Completed PHASE1 INTERVENTIONAL 6-arm NCT01910883

Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects

Finafloxacin - A Double-blind, Placebo-controlled, Randomised, Dose-escalating, Crossover Study to Determine the Safety and Tolerability of Single and Multiple Intravenous Doses of Finafloxacin in Healthy Subjects

Sponsor: MerLion Pharmaceuticals GmbH

Conditions Healthy

Interventions Finafloxacin i.v. solution 1000 mg Finafloxacin i.v. solution 200 mg Finafloxacin i.v. solution 400 mg Finafloxacin i.v. solution 600 mg Finafloxacin i.v. solution 800 mg Placebo i.v. solution

Updated 5 times since 2017 Last updated: Jul 25, 2013 Started: Sep 30, 2010 Primary completion: Mar 31, 2012 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy and is currently completed. MerLion Pharmaceuticals GmbH leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

MerLion Pharmaceuticals GmbH

Data source: MerLion Pharmaceuticals GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leeds, United Kingdom